EXTON, PA — Frontage Laboratories, Inc. hosted a grand opening event to unveil its newest Contract Research, Development, and Manufacturing Organization (CRDMO) facility, a 46,300-square-foot, Good Manufacturing Practice (GMP) site located at 240 Sierra Drive in Exton, Pennsylvania.
The facility is a major addition to Frontage’s infrastructure, underscoring the company’s commitment to accelerating pharmaceutical and biotech development. Equipped with nine GMP suites, the site is designed to handle a wide range of manufacturing needs. These include two high-potent suites, two aseptic suites, and five non-sterile suites capable of supporting the production of injectables, tablets, capsules, and various topical and nasal formulations. For formulation and analytical work, the facility also features two formulation development labs and three analytical labs, including one dedicated to microbiology.
By offering end-to-end services for clinical supplies—including formulation development, manufacturing, analytical testing, and distribution—the facility provides a comprehensive solution to meet the demands of pharmaceutical and biotech clients.
A Landmark Advancement for Frontage
The unveiling of this facility represents a significant milestone for Frontage Laboratories as it expands its CRDMO footprint. This addition strengthens its existing capabilities, which include drug substance synthesis, DMPK studies, safety and toxicology evaluations, bioanalytical support, and clinical trial services.
Dr. Song Li, Founder and Executive Chairman of Frontage, expressed the importance of the launch during the event. “We are grateful to all who joined us to share in our joyous occasion. The grand opening of this new CRDMO marks a significant milestone for us in the CDMO and clinical trial material supply space.”
Echoing Dr. Li’s sentiments, Dr. Wentao Zhang, Co-CEO of Frontage Laboratories, highlighted the strategic value of the facility. “For years, Frontage has been expanding by opening new sites and acquiring existing ones. The launch of our new state-of-the-art CDMO facility significantly enhances our manufacturing capabilities, positioning us closer to our clients and enabling us to respond more efficiently to their evolving development and supply needs.”
A New Era for Pharmaceutical and Biotech Innovation
With this addition, Frontage Laboratories continues to solidify its role as a leader in pharmaceutical and biotech innovation. The facility’s state-of-the-art technology and expansive service offerings are expected to provide clients with greater flexibility and streamlined solutions, ensuring accelerated timelines and improved outcomes for critical drug development programs.
The Exton facility not only broadens Frontage’s capacity but also strengthens its ability to meet the growing and diverse needs of its global client base. This milestone reinforces the company’s mission to bring innovative therapies to market more efficiently and effectively.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.